Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF

What Was Tested

Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.

As a result, there has been great interest measuring it during the course of treatment.

The prognostic implications in both short-term and follow-up changes in NTproBNP need further clarification.

Who Took Part

The study group was 795 subjects.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Baseline, 48-72 hour, and 30-day NTproBNP levels were measured in 795 subjects in the ASCEND-HF trial.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The subjects were allocated by chance, so the BNP (Nesiritide) group and the comparison group should start out alike.

Blinding on both sides kept the subjects and researchers unaware of who received BNP (Nesiritide).

What Was Measured

As a result, there has been great interest measuring it during the course of treatment.

PubMed files the paper under topics including Acute Disease, Biomarkers, Heart Failure, Natriuretic Agents, Natriuretic Peptide, Brain, Outcome Assessment, Health Care and Peptide Fragments.

Author keywords: acute heart failure and nesiritide.

What This Means in Plain Language

The paper is a randomized and double-blind study of BNP (Nesiritide) in 795 subjects.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Journal of cardiac failure), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.